Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556463 · ClinicalTrials.gov registry record · Phase 1
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT02556463 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 53 participants.
The verdict
NCT02556463, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumors and in combination with durvalumab in subjects with solid tumors.
Interventions
- BIOLOGICAL durvalumab
- DRUG MEDI9197
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2018-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556463
The ClinicalTrials.gov registry entry for NCT02556463 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which durvalumab is the first listed.
NCT02556463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02556463 about?
NCT02556463 is a clinical study titled "A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors". To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumors and in combination with durvalumab in subjects with solid tumors.
What is the current status of trial NCT02556463?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2015-11-04. Estimated completion is 2018-10-26.
What interventions are being tested in trial NCT02556463?
The interventions under investigation include: durvalumab (BIOLOGICAL), MEDI9197 (DRUG).
Who is sponsoring clinical trial NCT02556463?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.